BRIEF published on 05/16/2026 at 00:05, 1 day 20 hours ago Onco-Innovations fait progresser les tests de qualité pour l'inhibiteur de PNKP Normes De Qualité Recherche Sur Le Cancer Validation De L'inhibiteur De PNKP Préparation Des Essais Cliniques Onco-Innovations Limitée
BRIEF published on 05/16/2026 at 00:05, 1 day 20 hours ago Onco-Innovations Advances Quality Testing for PNKP Inhibitor Cancer Research Quality Standards Onco-Innovations Limited PNKP Inhibitor Validation Clinical Trials Preparation
PRESS RELEASE published on 05/16/2026 at 00:00, 1 day 20 hours ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate Onco-Innovations advances CMC program by initiating analytical method validation for ONC010 API, partnering with Dalton Pharma Services for IND-enabling studies and Phase I clinical development support IND-enabling Studies Onco-Innovations Dalton Pharma Services CMC Program Analytical Method Validation
BRIEF published on 05/13/2026 at 00:05, 4 days 20 hours ago Onco-Innovations collabore avec AstraZeneca sur l'IA en oncologie Intelligence Artificielle Modélisation Prédictive Partenariat Avec AstraZeneca Collaboration En Matière De Recherche Résultats En Oncologie
BRIEF published on 05/13/2026 at 00:05, 4 days 20 hours ago Onco-Innovations Collaborates with AstraZeneca on AI in Oncology Artificial Intelligence Research Collaboration Predictive Modeling AstraZeneca Partnership Oncology Outcomes
PRESS RELEASE published on 05/13/2026 at 00:00, 4 days 20 hours ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI Onco-Innovations Limited announces collaboration with AstraZeneca for the PROmAI program to Predict Oncology Outcomes using Multimodal Artificial Intelligence in oncology research and development AstraZeneca Multimodal AI Onco-Innovations Limited Oncology Outcomes PROmAI Program
BRIEF published on 05/09/2026 at 00:05, 8 days 20 hours ago Onco-Innovations Advances PNKP Inhibitor Development with Nucro-Technics' Bioanalysis Onco-Innovations PNKP Inhibitor Nucro-Technics Bioanalysis LC-MS
BRIEF published on 05/09/2026 at 00:05, 8 days 20 hours ago Onco-Innovations fait progresser le développement d'inhibiteurs de PNKP grâce à la bioanalyse de Nucro-Technics. Onco-Innovations Inhibiteur De PNKP Nucro-Techniques LC-MS Bioanalyse
PRESS RELEASE published on 05/09/2026 at 00:00, 8 days 20 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology Onco-Innovations Limited announces Nucro-Technics Inc.'s advanced bioanalytical work on PNKP Inhibitor Technology, moving towards clinical evaluation Onco-Innovations Limited PNKP Inhibitor Technology Nucro-Technics Inc. Bioanalytical Work Clinical Evaluation
BRIEF published on 05/06/2026 at 00:05, 11 days 20 hours ago Onco-Innovations and GSK Collaborate to Enhance Oncology Evidence Clinical Trials Oncology GSK Real-world Data Onco-Innovations
Published on 05/16/2026 at 01:15, 1 day 19 hours ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 1 day 20 hours ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 1 day 21 hours ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/16/2026 at 16:08, 1 day 4 hours ago The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 2 days ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 2 days 2 hours ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 15:08, 2 days 5 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 2 days 5 hours ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 2 days 10 hours ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 3 days 11 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 4 days 2 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
